B-cell depletion enhances the antileukemic function of CD20-specific cTCR⁺ T cells. (A) WT or B cell–depleted mice received 2 × 10⁷ BM185-mCD20/Thy1.1-ffLuc-Neo intravenously and were treated 3 days later with 10⁷ MB20-18 or vector-transduced Thy1.1⁺CD8⁺ T cells. 1F5 (200 μg) was injected 4 days before T-cell injection. Serial quantitation of leukemia bioluminescent signal was performed after T-cell injection. Data are representative of 2 experiments with 4 mice per group. (B) Survival of mice after treatment. Cumulative data from 2 separate experiments with 8 mice per group total are depicted. The first experiment was censored at 154 days and the second at 118 days, when data analysis was performed. P value was obtained with the log-rank test. (C) Peripheral blood analysis of mice 3 days after T-cell injection. P value was obtained by 1-way ANOVA analysis. Data are representative of 2 experiments with 4 mice per group. Data points and bar graphs represent mean ± SE.